Anne Caron
26 Avenue Du Dr Arnold Netter
Paris, 75012, France
Paris, 75012, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Measuring the intensity of restraint during care in children: Validation of the Pric scale
Journal: Soins; la revue de reference infirmiere
Published: January 31, 2024
Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
Journal: Oncoimmunology
Published: September 06, 2021
SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.
Journal: Molecular cancer therapeutics
Published: May 08, 2020
Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader.
Journal: EJNMMI research
Published: October 08, 2019
An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities.
Journal: Molecular cancer therapeutics
Published: August 26, 2019
A simple tool to measure procedural restraint intensity in children: validation of the PRIC (Procedural Restraint Intensity in Children) scale.
Journal: Heliyon
Published: June 01, 2018
Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors.
Journal: Journal of medicinal chemistry
Published: November 18, 2014
Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease.
Journal: Journal of inherited metabolic disease
Published: March 04, 2014
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 18, 2013
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 18, 2011
Showing 1-10 of 10
Last Updated: 09/26/2026